EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2024 to Q3 2025

Type / Class
Equity / Common Shares, with no par value
Symbol
EPRX on Nasdaq
Shares outstanding
50,973,571
Price per share
$6.40
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
12,813,323
Total reported value
$75,287,324
% of total 13F portfolios
0%
Share change
+10,843,247
Value change
+$63,953,896
Number of holders
27
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MANCHESTER MANAGEMENT CO LLC 11% $34,453,386 5,839,557 JAMES E. BESSER 31 Dec 2024
Freedman Joseph S. 10% $29,215,375 5,533,215 Joseph S. Freedman 24 Sep 2025
Beutel, Goodman & Co Ltd. 8% $23,947,504 4,058,899 Beutel, Goodman & Co Ltd. 30 Sep 2025
DISBROW ROBERT 7% $21,052,085 3,568,150 Robert Disbrow 30 Sep 2025

As of 30 Sep 2025, 27 institutional investors reported holding 12,813,323 shares of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX). This represents 25% of the company’s total 50,973,571 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) together control 25% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Beutel, Goodman & Co Ltd. 8% 4,058,899 0.14% $23,920,000
Vivo Capital, LLC 2.6% 1,350,000 0.64% $7,965,000
Balyasny Asset Management L.P. 2.6% 1,350,000 0.02% $7,965,000
SCOTIA CAPITAL INC. 2.5% 1,277,885 -1.1% 0.03% $7,254,710
GREAT POINT PARTNERS LLC 2.4% 1,200,000 3% $7,080,000
Ally Bridge Group (NY) LLC 1.8% 915,000 4.5% $5,398,500
Logos Global Management LP 1.8% 900,000 0.52% $5,310,000
ROYAL BANK OF CANADA 0.84% 428,804 +0.05% 0% $2,530,000
Velan Capital Investment Management LP 0.69% 352,000 2% $2,076,800
Affinity Asset Advisors, LLC 0.59% 300,000 0.16% $1,770,000
Alyeska Investment Group, L.P. 0.49% 250,000 0% $1,475,000
UBS Group AG 0.19% 95,756 +155% 0% $564,960
INGALLS & SNYDER LLC 0.12% 59,100 +59% 0.01% $349,000
BANK OF AMERICA CORP /DE/ 0.09% 45,577 +263% 0% $268,904
GOLDMAN SACHS GROUP INC 0.08% 40,100 +0.75% 0% $236,590
BANK OF MONTREAL /CAN/ 0.07% 37,250 0% 0% $219,431
RAYMOND JAMES FINANCIAL INC 0.07% 33,373 +173% 0% $196,901
Guardian Partners Inc. 0.05% 24,130 0.01% $147,409
ACADIAN ASSET MANAGEMENT LLC 0.04% 21,400 0% $125,000
JPMORGAN CHASE & CO 0.03% 16,467 -12% 0% $97,155
CIBC WORLD MARKET INC. 0.03% 15,000 0% 0% $88,362
Integrated Wealth Concepts LLC 0.02% 12,000 0% $70,800
TCI Wealth Advisors, Inc. 0.02% 11,000 0% $64,900
TD Waterhouse Canada Inc. 0.02% 9,600 0% 0% $56,227
Federation des caisses Desjardins du Quebec 0.02% 9,091 0% $51,590

Institutional Holders of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 12,813,323 $75,287,324 +$63,953,896 $5.90 27
2025 Q2 1,970,076 $10,889,810 -$1,049,982 $5.76 14
2025 Q1 2,167,593 $7,087,336 +$1,118,949 $3.28 11
2024 Q4 1,826,270 $5,634,759 +$50,501 $3.17 9
2024 Q3 1,798,968 $4,545,745 +$185,000 $2.63 8
2024 Q2 1,727,190 $4,433,025 +$4,433,018 $2.58 8